NCT04727398

Brief Summary

Intraocular surgery could induce vitreous degeneration and then abnormal posterior vitreous detachment (PVD) could occur including vitreoschisis and partial-thickness PVD. Vitreomacular interface (VMI) abnormalities such as epimacular membrane were observed following many intraocular surgeries. The incidence of peripheral break and epimacular membrane (EMM) after pneumatic retinopexy were 11.7% and 4-11%, respectively. Although multiple intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections induced PVD of 5.6%, but peripheral break was reported as only 0.67%. The incidence of rhegmatogenous retinal detachment (RRD) after phacoemulsification is gradually increased with time. The accumulative risk of RRD was increased from 0.27% at 1 year to 1.27% at 20 years after phacoemulsification.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
92

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 24, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 27, 2021

Completed
7 months until next milestone

Study Start

First participant enrolled

September 3, 2021

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

October 10, 2023

Status Verified

October 1, 2023

Enrollment Period

3.3 years

First QC Date

January 24, 2021

Last Update Submit

October 7, 2023

Conditions

Keywords

posterior vitreous detachmentphacoemulsification

Outcome Measures

Primary Outcomes (1)

  • The incidence of PVD after phacoemulsification

    incidence of complete PVD

    12 months

Secondary Outcomes (1)

  • The incidence of VMI disorders

    12 months

Study Arms (1)

Cataract patients who was scheduled for phacoemulsification

OTHER

Wide-field optical coherence tomography was performed before the surgery, and then was done at 1, 3, 6 and 12 months following the phacoemulsification.

Device: Wide-field optical coherence tomography (Optovue®)

Interventions

Merged 4 images for wide-filed OCT-based PVD classification, 2 vertical line images and 2 horizontal line images

Cataract patients who was scheduled for phacoemulsification

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Cataract patients who was scheduled for phacoemulsification
  • Age \>50 years
  • No complete PVD was detected by OCT
  • Can be taken the wide-field OCT images
  • Written informed consent

You may not qualify if:

  • Secondary cataract)
  • History of ocular trauma or head trauma
  • Systemic diseases that can cause the intraocular problems such as connective tissue disease
  • History of other ocular diseases such as glaucoma, uveitis and vitreoretinal disorders
  • History of intraocular laser treatment
  • History of intraocular surgery such as intravitreal drug injection
  • Withdrawal Criteria:
  • Intraoperative complications such as posterior capsular rupture and zonule dialysis
  • Postoperative complications such as vitreous hemorrhage and postoperative endophthalmitis
  • Undergo the intraocular surgery during the follow-up period
  • Receiving the intraocular laser treatment during the follow-up period such as laser capsulotomy and panretinal photocoagulation
  • Having the ocular trauma or head trauma during the follow-up period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Khon Kaen University

Khon Kaen, 40002, Thailand

RECRUITING

MeSH Terms

Conditions

Vitreous Detachment

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Suthasinee Sinawat, MD

    KKU Eye Center, Department of Ophthalmology, Faculty of Medicine, Khon Kaen University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Suthasinee Sinawat, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 24, 2021

First Posted

January 27, 2021

Study Start

September 3, 2021

Primary Completion

December 30, 2024

Study Completion

June 30, 2025

Last Updated

October 10, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations